ArticleCPT: pharmacometrics & systems pharmacology2021

Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase-positive non-small cell lung cancer: Exposure-response analyses of pivotal ALTA study.

No numbers read from the abstract.

Not cited yet